Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
NCT ID: NCT07145502
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
76 participants
OBSERVATIONAL
2022-09-19
2027-09-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis
NCT07146087
Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study
NCT02239393
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
NCT00813969
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
NCT02495766
Autologous Stem Cell Transplant for Multiple Sclerosis
NCT01099930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B1
* Age 6-70
* Diagnosis of one of the eligible syndromes by neurologist or immunologist
* Unresponsive or partially responsive to conventional therapy
* Informed consent provided
Allogeneic MSC infusions (IV)
Optional T-reg therapy (experimental/compassionate-use basis)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogeneic MSC infusions (IV)
Optional T-reg therapy (experimental/compassionate-use basis)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of one of the eligible syndromes by neurologist or immunologist
* Unresponsive or partially responsive to conventional therapy
* Informed consent provided
Exclusion Criteria
* Severe systemic infection
* Contraindications to IV biologics
6 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocells Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biocells Medical
Warsaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bio120001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.